Specifically, recent work by Franco et al has unveiled metabolic reprogramming events and actionable metabolic targets, in particular mTOR, in pancreatic cancer cells in response to palbociclib (Franco et al, 2016). This evidence concerns the gene MTOR and familial pancreatic carcinoma.